Israel gains breakthrough in developing COVID-19 antibody: minister

Grant Boone
May 6, 2020

Israel Institute for Biological Research (IIBR) has developed an antibody which can neutralise the virus responsible for COVID-19 within the bodies of those infected, the country's Defense Minister Naftali Bennett has said.

Meanwhile, the USA is planning to begin treating some of the most seriously ill coronavirus patients with the antiviral medication Remdesivir, the maker of the drug recently said.

British researcher David Collier tweeted, "Most people on hearing the news that Israel has made a breakthrough in the development of an antibody that neutralizes the coronavirus: 'Wow, I so hope that's true.' But to anti-Semites: 'Well that just proves they did create the virus in the first place'".

The development phase of what may be a future vaccine is finished, according to The Times of Israel, as researchers plan to patent and mass produce the discovery.

On Monday, Netanyahu pledged $60 million from Israel toward global efforts to develop therapies, diagnostic kits, and a vaccine for COVID-19 as part of an worldwide summit of world leaders looking to raise $11 billion.

It quoted IIBR Director Shmuel Shapira as saying that the antibody formula was being patented, after which an global manufacturer would be sought to mass-produce it.

United Kingdom starts testing coronavirus contact tracing app
Mr Hancock also joined Isle of Wight Radio's Breakfast Show team this morning, when we put your questions to him. The app is part of the government's plan to ease lockdown restrictions.

The statement comes after the defense minister's visit to the Israel Institute for Biological Research (IIBR), in which he claimed that he was briefed "on a significant breakthrough in finding an antidote for the coronavirus".

The researcher said that the antibody had been shown to delay the development of the coronavirus in laboratory experiments.

Numerous research teams all over the world are participating in the race to develop a vaccine for COVID-19.

Also in April, an Israeli scientist was awarded a United States patent for his innovative vaccine design for the corona family of viruses and indicated that he was on track to develop a vaccine for SARS CoV2.

The approval allowed patients who were extremely ill with the COVID-19 to be treated by this drug, that was created by Gilead Sciences. These antibodies, however, were reportedly polyclonal or extracted from two or more cells of varied ancestry. It has now been diverted to treat coronavirus where it is showing good results. According to PTI, the IIBR has conducted some clinical trials.

Other reports by

Discuss This Article